A. Joosse

发表

Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study.

R. Herings, H. Guchelaar, T. Nijsten, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?

R. Herings, H. Guchelaar, T. Nijsten, 2007, European journal of cancer.

Reactive oxygen species and melanoma: an explanation for gender differences in survival?

J. Coebergh, A. Eggermont, C. V. van Eijck, 2010, Pigment cell & melanoma research.

Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment

D. Hesselink, R. Mathijssen, R. V. van Schaik, 2019, Journal of Immunotherapy for Cancer.

Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study.

R. Herings, H. Guchelaar, T. Nijsten, 2009, The Journal of investigative dermatology.

Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy

R. Herings, H. Guchelaar, T. Nijsten, 2009, Melanoma research.

Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy

A. Testori, V. Bataille, S. Gandini, 2013, PloS one.

Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials.

J. Coebergh, A. Eggermont, T. Nijsten, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.

J. Coebergh, A. Eggermont, T. Nijsten, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extra attention for melanoma among elderly men

J. Coebergh, A. Joosse, E. Vries, 2010, Nature Reviews Clinical Oncology.

Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma

T. Nijsten, M. Wakkee, A. Veldt, 2022, The British journal of dermatology.

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.

J. Aerts, R. Mathijssen, N. Vermeer, 2022, European journal of cancer.

Statin use and its effect on all-cause mortality of melanoma patients

D. Schadendorf, T. Nijsten, E. Livingstone, 2017 .

Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients.

J. Aerts, R. Peeters, R. Mathijssen, 2020, Thyroid : official journal of the American Thyroid Association.

The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.

J. Aerts, C. H. van der Leest, R. Mathijssen, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Gender differences in melanoma survival: female patients have a decreased risk of metastasis.

J. Coebergh, A. Eggermont, T. Nijsten, 2011, The Journal of investigative dermatology.

Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.

A. Jager, R. Danesi, R. Mathijssen, 2022, Cancer treatment reviews.

Gender Differences in Melanoma Progression and Survival

A. Joosse, 2014 .

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report

R. Mathijssen, R. Debets, S. Veenbergen, 2023, Journal for ImmunoTherapy of Cancer.

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma

M. J. van den Bent, C. Verhoef, D. Grünhagen, 2022, ESMO open.

Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies

A. Eggermont, A. Testori, M. Suppa, 2018, Melanoma research.

Sex Differences in Melanoma Survival are Not Related to Mitotic Rate of the Primary Tumor

J. Coebergh, R. Scolyer, A. Eggermont, 2015, Annals of Surgical Oncology.

Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study

D. Schadendorf, B. Schilling, T. Nijsten, 2014, Cancer medicine.

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

C. Blank, J. D. de Groot, R. Koornstra, 2017, Acta oncologica.

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

O. Dekkers, C. Blank, G. Hospers, 2022, British Journal of Cancer.

Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data

M. J. van den Bent, M. D. de Jonge, J. Schouten, 2023, Cancers.

Oncological healthcare providers’ perspectives on appropriate melanoma survivorship care: a qualitative focus group study

T. Nijsten, M. Wakkee, M. Lugtenberg, 2023, BMC Cancer.

Fecal Microbiota Transplantation for Immune Checkpoint Inhibitor-Induced Colitis Is Safe and Contributes to Recovery: Two Case Reports.

A. Joosse, E. M. Terveer, M. Barnhoorn, 2023, Journal of immunotherapy.